Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Véniant MM[au]:

Search results

Items: 1 to 50 of 59

1.

Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies For The Treatment Of Obesity, Do Agonists = Antagonists?

Killion EA, Lu SC, Fort M, Yamada Y, Véniant MM, Lloyd DJ.

Endocr Rev. 2019 Sep 12. pii: bnz002. doi: 10.1210/endrevbnz002. [Epub ahead of print]

PMID:
31511855
2.

Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies For The Treatment Of Obesity, Do Agonists = Antagonists?

Killion EA, Lu SC, Fort M, Yamada Y, Véniant MM, Lloyd DJ.

Endocr Rev. 2019 Sep 12. pii: bnz002. doi: 10.1210/endrev/bnz002. [Epub ahead of print]

PMID:
31511854
3.

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.

Killion EA, Wang J, Yie J, Shi SD, Bates D, Min X, Komorowski R, Hager T, Deng L, Atangan L, Lu SC, Kurzeja RJM, Sivits G, Lin J, Chen Q, Wang Z, Thibault SA, Abbott CM, Meng T, Clavette B, Murawsky CM, Foltz IN, Rottman JB, Hale C, Véniant MM, Lloyd DJ.

Sci Transl Med. 2018 Dec 19;10(472). pii: eaat3392. doi: 10.1126/scitranslmed.aat3392.

PMID:
30567927
4.

FGF21 acts as a negative regulator of bile acid synthesis.

Chen MM, Hale C, Stanislaus S, Xu J, Véniant MM.

J Endocrinol. 2018 May;237(2):139-152. doi: 10.1530/JOE-17-0727.

PMID:
29615519
5.

Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys.

Xiong Y, Walker K, Min X, Hale C, Tran T, Komorowski R, Yang J, Davda J, Nuanmanee N, Kemp D, Wang X, Liu H, Miller S, Lee KJ, Wang Z, Véniant MM.

Sci Transl Med. 2017 Oct 18;9(412). pii: eaan8732. doi: 10.1126/scitranslmed.aan8732. Erratum in: Sci Transl Med. 2018 Aug 29;10(456):.

PMID:
29046435
6.

A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys.

Stanislaus S, Hecht R, Yie J, Hager T, Hall M, Spahr C, Wang W, Weiszmann J, Li Y, Deng L, Winters D, Smith S, Zhou L, Li Y, Véniant MM, Xu J.

Endocrinology. 2017 May 1;158(5):1314-1327. doi: 10.1210/en.2016-1917.

PMID:
28324011
7.

FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists.

Li X, Stanislaus S, Asuncion F, Niu QT, Chinookoswong N, Villasenor K, Wang J, Wong P, Boyce R, Dwyer D, Han CY, Chen MM, Liu B, Stolina M, Ke HZ, Ominsky MS, Véniant MM, Xu J.

J Bone Miner Res. 2017 Apr;32(4):834-845. doi: 10.1002/jbmr.2936. Epub 2016 Sep 9.

8.

Haploinsufficiency of the Insulin Receptor in the Presence of a Splice-Site Mutation in Ppp2r2a Results in a Novel Digenic Mouse Model of Type 2 Diabetes.

Goldsworthy M, Bai Y, Li CM, Ge H, Lamas E, Hilton H, Esapa CT, Baker D, Baron W, Juan T, Véniant MM, Lloyd DJ, Cox RD.

Diabetes. 2016 May;65(5):1434-46. doi: 10.2337/db15-1276. Epub 2016 Feb 11.

9.

Trefoil Factor 3 (TFF3) Is Regulated by Food Intake, Improves Glucose Tolerance and Induces Mucinous Metaplasia.

Ge H, Gardner J, Wu X, Rulifson I, Wang J, Xiong Y, Ye J, Belouski E, Cao P, Tang J, Lee KJ, Coberly S, Wu X, Gupte J, Miao L, Yang L, Nguyen N, Shan B, Yeh WC, Véniant MM, Li Y, Baribault H.

PLoS One. 2015 Jun 17;10(6):e0126924. doi: 10.1371/journal.pone.0126924. eCollection 2015.

10.

Pharmacologic Effects of FGF21 Are Independent of the "Browning" of White Adipose Tissue.

Véniant MM, Sivits G, Helmering J, Komorowski R, Lee J, Fan W, Moyer C, Lloyd DJ.

Cell Metab. 2015 May 5;21(5):731-8. doi: 10.1016/j.cmet.2015.04.019.

11.

C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.

Du X, Hinklin RJ, Xiong Y, Dransfield P, Park J, Kohn TJ, Pattaropong V, Lai S, Fu Z, Jiao X, Chow D, Jin L, Davda J, Veniant MM, Anderson DA, Baer BR, Bencsik JR, Boyd SA, Chicarelli MJ, Mohr PJ, Wang B, Condroski KR, DeWolf WE, Conn M, Tran T, Yang J, Aicher TD, Medina JC, Coward P, Houze JB.

ACS Med Chem Lett. 2014 Nov 22;5(12):1284-9. doi: 10.1021/ml500341w. eCollection 2014 Dec 11.

12.

A mutation in Ampd2 is associated with nephrotic syndrome and hypercholesterolemia in mice.

Helmering J, Juan T, Li CM, Chhoa M, Baron W, Gyuris T, Richards WG, Turk JR, Lawrence J, Cosgrove PA, Busby J, Kim KW, Kaufman SA, Cummings C, Carlson G, Véniant MM, Lloyd DJ.

Lipids Health Dis. 2014 Oct 31;13:167. doi: 10.1186/1476-511X-13-167.

13.

Molecular targeting of the GK-GKRP pathway in diabetes.

Hale C, Lloyd DJ, Pellacani A, Véniant MM.

Expert Opin Ther Targets. 2015 Jan;19(1):129-39. doi: 10.1517/14728222.2014.965681. Epub 2014 Oct 17. Review.

PMID:
25324018
14.

Characterization of a novel glucokinase activator in rat and mouse models.

Lu M, Li P, Bandyopadhyay G, Lagakos W, Dewolf WE Jr, Alford T, Chicarelli MJ, Williams L, Anderson DA, Baer BR, McVean M, Conn M, Véniant MM, Coward P.

PLoS One. 2014 Feb 12;9(2):e88431. doi: 10.1371/journal.pone.0088431. eCollection 2014.

15.

Piperazine oxadiazole inhibitors of acetyl-CoA carboxylase.

Bourbeau MP, Siegmund A, Allen JG, Shu H, Fotsch C, Bartberger MD, Kim KW, Komorowski R, Graham M, Busby J, Wang M, Meyer J, Xu Y, Salyers K, Fielden M, Véniant MM, Gu W.

J Med Chem. 2013 Dec 27;56(24):10132-41. doi: 10.1021/jm401601s. Epub 2013 Dec 11.

PMID:
24294923
16.

Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors.

Lloyd DJ, St Jean DJ Jr, Kurzeja RJ, Wahl RC, Michelsen K, Cupples R, Chen M, Wu J, Sivits G, Helmering J, Komorowski R, Ashton KS, Pennington LD, Fotsch C, Vazir M, Chen K, Chmait S, Zhang J, Liu L, Norman MH, Andrews KL, Bartberger MD, Van G, Galbreath EJ, Vonderfecht SL, Wang M, Jordan SR, Véniant MM, Hale C.

Nature. 2013 Dec 19;504(7480):437-40. doi: 10.1038/nature12724. Epub 2013 Nov 13.

PMID:
24226772
17.

FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/β-Klotho bispecific protein.

Smith R, Duguay A, Bakker A, Li P, Weiszmann J, Thomas MR, Alba BM, Wu X, Gupte J, Yang L, Stevens J, Hamburger A, Smith S, Chen J, Komorowski R, Moore KW, Véniant MM, Li Y.

PLoS One. 2013 Apr 22;8(4):e61432. doi: 10.1371/journal.pone.0061432. Print 2013.

18.

Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes.

Hecht R, Li YS, Sun J, Belouski E, Hall M, Hager T, Yie J, Wang W, Winters D, Smith S, Spahr C, Tam LT, Shen Z, Stanislaus S, Chinookoswong N, Lau Y, Sickmier A, Michaels ML, Boone T, Véniant MM, Xu J.

PLoS One. 2012;7(11):e49345. doi: 10.1371/journal.pone.0049345. Epub 2012 Nov 27.

19.

Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex.

Foltz IN, Hu S, King C, Wu X, Yang C, Wang W, Weiszmann J, Stevens J, Chen JS, Nuanmanee N, Gupte J, Komorowski R, Sekirov L, Hager T, Arora T, Ge H, Baribault H, Wang F, Sheng J, Karow M, Wang M, Luo Y, McKeehan W, Wang Z, Véniant MM, Li Y.

Sci Transl Med. 2012 Nov 28;4(162):162ra153. doi: 10.1126/scitranslmed.3004690.

20.

Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys.

Véniant MM, Komorowski R, Chen P, Stanislaus S, Winters K, Hager T, Zhou L, Wada R, Hecht R, Xu J.

Endocrinology. 2012 Sep;153(9):4192-203. doi: 10.1210/en.2012-1211. Epub 2012 Jul 13.

PMID:
22798348
21.

FGF21 promotes metabolic homeostasis via white adipose and leptin in mice.

Véniant MM, Hale C, Helmering J, Chen MM, Stanislaus S, Busby J, Vonderfecht S, Xu J, Lloyd DJ.

PLoS One. 2012;7(7):e40164. doi: 10.1371/journal.pone.0040164. Epub 2012 Jul 6.

22.

Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.

Hale C, Chen MM, Stanislaus S, Chinookoswong N, Hager T, Wang M, Véniant MM, Xu J.

Endocrinology. 2012 Jan;153(1):69-80. doi: 10.1210/en.2010-1262. Epub 2011 Nov 8.

PMID:
22067317
23.

A volumetric method for quantifying atherosclerosis in mice by using microCT: comparison to en face.

Lloyd DJ, Helmering J, Kaufman SA, Turk J, Silva M, Vasquez S, Weinstein D, Johnston B, Hale C, Véniant MM.

PLoS One. 2011 Apr 18;6(4):e18800. doi: 10.1371/journal.pone.0018800.

24.

Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice.

Gu W, Lloyd DJ, Chinookswong N, Komorowski R, Sivits G Jr, Graham M, Winters KA, Yan H, Boros LG, Lindberg RA, Véniant MM.

J Pharmacol Exp Ther. 2011 Jul;338(1):70-81. doi: 10.1124/jpet.111.179986. Epub 2011 Apr 6.

PMID:
21471191
25.

Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor.

Gu W, Winters KA, Motani AS, Komorowski R, Zhang Y, Liu Q, Wu X, Rulifson IC, Sivits G Jr, Graham M, Yan H, Wang P, Moore S, Meng T, Lindberg RA, Véniant MM.

Am J Physiol Endocrinol Metab. 2010 Oct;299(4):E624-32. doi: 10.1152/ajpendo.00102.2010. Epub 2010 Jul 20.

26.

Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221).

Véniant MM, Hale C, Hungate RW, Gahm K, Emery MG, Jona J, Joseph S, Adams J, Hague A, Moniz G, Zhang J, Bartberger MD, Li V, Syed R, Jordan S, Komorowski R, Chen MM, Cupples R, Kim KW, St Jean DJ Jr, Johansson L, Henriksson MA, Williams M, Vallgårda J, Fotsch C, Wang M.

J Med Chem. 2010 Jun 10;53(11):4481-7. doi: 10.1021/jm100242d.

PMID:
20465278
27.

Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice.

Lau YY, Ma P, Gibiansky L, Komorowski R, Wang J, Wang G, Yan H, Véniant MM, Kakkar T.

AAPS J. 2009 Dec;11(4):700-9. doi: 10.1208/s12248-009-9150-z. Epub 2009 Oct 23.

28.

Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice.

Li X, Ge H, Weiszmann J, Hecht R, Li YS, Véniant MM, Xu J, Wu X, Lindberg R, Li Y.

FEBS Lett. 2009 Oct 6;583(19):3230-4. doi: 10.1016/j.febslet.2009.09.012. Epub 2009 Sep 12.

29.

Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia.

Gu W, Yan H, Winters KA, Komorowski R, Vonderfecht S, Atangan L, Sivits G, Hill D, Yang J, Bi V, Shen Y, Hu S, Boone T, Lindberg RA, Véniant MM.

J Pharmacol Exp Ther. 2009 Dec;331(3):871-81. doi: 10.1124/jpet.109.157685. Epub 2009 Aug 31.

PMID:
19720878
30.

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.

Xu J, Stanislaus S, Chinookoswong N, Lau YY, Hager T, Patel J, Ge H, Weiszmann J, Lu SC, Graham M, Busby J, Hecht R, Li YS, Li Y, Lindberg R, Véniant MM.

Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1105-14. doi: 10.1152/ajpendo.00348.2009. Epub 2009 Aug 25.

31.

Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.

Lloyd DJ, Helmering J, Cordover D, Bowsman M, Chen M, Hale C, Fordstrom P, Zhou M, Wang M, Kaufman SA, Véniant MM.

Diabetes Obes Metab. 2009 Jul;11(7):688-99. doi: 10.1111/j.1463-1326.2009.01034.x.

PMID:
19527482
32.

Pancreatic islet expression profiling in diabetes-prone C57BLKS/J mice reveals transcriptional differences contributed by DBA loci, including Plagl1 and Nnt.

Anderson AA, Helmering J, Juan T, Li CM, McCormick J, Graham M, Baker DM, Damore MA, Véniant MM, Lloyd DJ.

Pathogenetics. 2009 Jan 22;2(1):1. doi: 10.1186/1755-8417-2-1.

33.

Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys.

Yan H, Gu W, Yang J, Bi V, Shen Y, Lee E, Winters KA, Komorowski R, Zhang C, Patel JJ, Caughey D, Elliott GS, Lau YY, Wang J, Li YS, Boone T, Lindberg RA, Hu S, Véniant MM.

J Pharmacol Exp Ther. 2009 Apr;329(1):102-11. doi: 10.1124/jpet.108.147009. Epub 2009 Jan 7.

PMID:
19129372
34.

Identification of three loci affecting HDL-cholesterol levels in a screen for chemically induced recessive mutations in mice.

Juan T, Véniant MM, Helmering J, Babij P, Baker DM, Damore MA, Bass MB, Gyuris T, Chhoa M, Li CM, Ebeling C, Amato J, Carlson GA, Lloyd DJ.

J Lipid Res. 2009 Mar;50(3):534-45. doi: 10.1194/jlr.M800471-JLR200. Epub 2008 Oct 29.

35.

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.

Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, Chen JL, Jung DY, Zhang Z, Ko HJ, Kim JK, Véniant MM.

Diabetes. 2009 Jan;58(1):250-9. doi: 10.2337/db08-0392. Epub 2008 Oct 7.

36.

Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.

Véniant MM, Hale C, Komorowski R, Chen MM, St Jean DJ, Fotsch C, Wang M.

Diabetes Obes Metab. 2009 Feb;11(2):109-17. doi: 10.1111/j.1463-1326.2008.00911.x. Epub 2008 May 12.

PMID:
18479468
37.

Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.

Miranda LP, Winters KA, Gegg CV, Patel A, Aral J, Long J, Zhang J, Diamond S, Guido M, Stanislaus S, Ma M, Li H, Rose MJ, Poppe L, Véniant MM.

J Med Chem. 2008 May 8;51(9):2758-65. doi: 10.1021/jm701522b. Epub 2008 Apr 15.

PMID:
18412318
38.

An optimized fast-performance liquid chromatography method for analyzing lipoprotein profiles using microliter volumes of serum.

Kim KW, McCormick J, Helmering J, Véniant MM, Wang M.

Anal Biochem. 2008 May 15;376(2):268-74. doi: 10.1016/j.ab.2008.02.028. Epub 2008 Mar 4.

PMID:
18358227
39.

Lipoprotein size and susceptibility to atherosclerosis--insights from genetically modified mouse models.

Véniant MM, Beigneux AP, Bensadoun A, Fong LG, Young SG.

Curr Drug Targets. 2008 Mar;9(3):174-89. Review.

40.

Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48-/-Lepob/ob mice devoid of ApoE or Ldlr.

Lloyd DJ, McCormick J, Helmering J, Kim KW, Wang M, Fordstrom P, Kaufman SA, Lindberg RA, Véniant MM.

Am J Physiol Endocrinol Metab. 2008 Mar;294(3):E496-505. Epub 2007 Dec 26.

41.

Co-receptor requirements for fibroblast growth factor-19 signaling.

Wu X, Ge H, Gupte J, Weiszmann J, Shimamoto G, Stevens J, Hawkins N, Lemon B, Shen W, Xu J, Veniant MM, Li YS, Lindberg R, Chen JL, Tian H, Li Y.

J Biol Chem. 2007 Oct 5;282(40):29069-72. Epub 2007 Aug 21.

42.

Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action.

Samuel VT, Choi CS, Phillips TG, Romanelli AJ, Geisler JG, Bhanot S, McKay R, Monia B, Shutter JR, Lindberg RA, Shulman GI, Veniant MM.

Diabetes. 2006 Jul;55(7):2042-50.

43.

Leptin: from animals to humans.

Veniant MM, LeBel CP.

Curr Pharm Des. 2003;9(10):811-8. Review.

PMID:
12678880
44.

Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice.

Véniant MM, Withycombe S, Young SG.

Arterioscler Thromb Vasc Biol. 2001 Oct;21(10):1567-70. Review.

PMID:
11597927
45.

Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100.

Véniant MM, Sullivan MA, Kim SK, Ambroziak P, Chu A, Wilson MD, Hellerstein MK, Rudel LL, Walzem RL, Young SG.

J Clin Invest. 2000 Dec;106(12):1501-10.

46.

A deficiency of microsomal triglyceride transfer protein reduces apolipoprotein B secretion.

Leung GK, Véniant MM, Kim SK, Zlot CH, Raabe M, Björkegren J, Neese RA, Hellerstein MK, Young SG.

J Biol Chem. 2000 Mar 17;275(11):7515-20.

47.

Lipoproteins containing apolipoprotein B-100 are secreted by the heart.

Véniant MM, Nielsen LB, Borén J, Young SG.

Trends Cardiovasc Med. 1999 Apr-May;9(3-4):103-7. Review.

PMID:
10578525
48.

Renal vascular and biochemical responses to systemic renin inhibition in dogs at low renal perfusion pressure.

Clozel JP, Véniant MM, Qiu C, Sprecher U, Wolfgang R, Fischli W.

J Cardiovasc Pharmacol. 1999 Nov;34(5):674-82.

PMID:
10547083
49.

Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice.

Raabe M, Véniant MM, Sullivan MA, Zlot CH, Björkegren J, Nielsen LB, Wong JS, Hamilton RL, Young SG.

J Clin Invest. 1999 May;103(9):1287-98.

50.

Insights into apolipoprotein B biology from transgenic and gene-targeted mice.

Véniant MM, Kim E, McCormick S, Borén J, Nielsen LB, Raabe M, Young SG.

J Nutr. 1999 Feb;129(2S Suppl):451S-455S. doi: 10.1093/jn/129.2.451S. Review.

PMID:
10064308

Supplemental Content

Loading ...
Support Center